IceCure Medical seeks Israeli approval for XSense cryoablation system
Ticker: ICCM · Form: 6-K · Filed: Feb 24, 2025 · CIK: 1584371
Sentiment: neutral
Topics: regulatory-filing, medical-device, israel
TL;DR
IceCure Medical filed for XSense system approval in Israel, a key market for their cryoablation tech.
AI Summary
On February 24, 2025, IceCure Medical Ltd. announced it has submitted a filing for regulatory approval of its next-generation XSense™ Cryoablation System in Israel. This submission marks a significant step towards potentially launching their advanced cryoablation technology in the Israeli market.
Why It Matters
This filing indicates IceCure Medical's progress in expanding the market reach of its innovative XSense cryoablation system, potentially leading to increased adoption and revenue.
Risk Assessment
Risk Level: low — The filing is a routine regulatory submission and does not contain immediate financial or operational risks.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and issuer of the press release.
- XSense™ Cryoablation System (product) — The product for which regulatory approval is being sought.
- February 24, 2025 (date) — Date of the press release and filing.
- Israel (location) — The country where regulatory approval is being sought.
FAQ
What is the specific regulatory body in Israel that IceCure Medical submitted its filing to?
The filing does not specify the exact regulatory body within Israel, only that a filing for regulatory approval has been submitted.
What is the expected timeline for the regulatory approval process in Israel?
The filing does not provide an estimated timeline for the regulatory approval process in Israel.
Does the filing mention any specific target indications for the XSense system in Israel?
The filing does not detail specific target indications for the XSense system in Israel.
Is this the first time IceCure Medical is seeking regulatory approval for the XSense system?
The filing refers to the 'next-generation' XSense system, implying prior versions or approvals may exist, but it does not explicitly state if this is the first approval sought for this specific generation.
What is the significance of filing in Israel for IceCure Medical?
Filing for regulatory approval in Israel is a step towards potentially launching their advanced cryoablation technology in the Israeli market, as stated in the filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 24, 2025 regarding IceCure Medical Ltd. (ICCM).